Protocol Ledger

NCT06930625 · Phase III · RECRUITING

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

Interventional Phase III clinical trial protocol NCT06930625 sponsored by Debiopharm International SA in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-26 Enrollment: 119 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06930625
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)119 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06930625
Protocol FieldVerified Registry Value
NCT IdentifierNCT06930625
Consolidated Lead SponsorDebiopharm International SA
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment119 participants (ESTIMATED)
Registered Start Date2025-11-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI